tiprankstipranks
Advertisement
Advertisement

Klotho Neurosciences Completes Reverse Merger Greenland Mines Acquisition

Story Highlights
  • Klotho Neurosciences closed its March 4, 2026 acquisition of Greenland Mines, gaining control of the massive Skaergaard palladium-gold-platinum project and planning a rebrand to Greenland Mines.
  • The Skaergaard Project, valued at about $68 billion in in-situ metals, is positioned as a major Western source of critical minerals that could ease U.S. and European reliance on Russian and South African palladium and platinum supplies.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Klotho Neurosciences Completes Reverse Merger Greenland Mines Acquisition

Claim 55% Off TipRanks

Klotho Neurosciences ( (KLTO) ) has issued an announcement.

On March 4, 2026, Klotho Neurosciences, Inc. announced it had closed the acquisition of Greenland Mines Corp., which controls an 80% stake and an option on the remaining 20% of the Skaergaard Project, one of the world’s largest undeveloped palladium, gold, and platinum deposits. The deal, structured entirely in convertible preferred stock and expected to be treated as a reverse merger, will leave former Greenland Mines holders with about 93% of the fully diluted shares, while Klotho plans to rebrand as Greenland Mines and operate two divisions: Natural Resources and Cell and Gene Therapy.

The Skaergaard Project carries an estimated $68 billion gross in-situ value in palladium, gold, and platinum, is fully permitted for exploration, and sits in what the company describes as a geopolitically secure, U.S.-proximate jurisdiction. Management positions the asset as a major Western alternative to heavily Russia- and South Africa-dependent supplies of palladium and platinum, arguing that its scale—equating to more than a decade of U.S. palladium consumption, plus potential by-products like gallium and vanadium—could materially reshape the company’s trajectory and bolster strategic mineral security for American and European industrial, clean energy, and defense stakeholders.

More about Klotho Neurosciences

Klotho Neurosciences, Inc. is a Nasdaq-listed company that operates in both biotechnology and natural resources. Its cell and gene therapy division focuses on treatments such as KLTO-202 for ALS, while its new Natural Resources division will concentrate on exploring and developing the Skaergaard palladium, gold, and platinum project in Southeast Greenland, targeting Western demand for critical minerals.

The company is shifting from a pure biotech profile to a diversified life sciences and strategic minerals player. Its market focus now spans investors seeking exposure to cutting-edge therapeutics and those interested in securing Western-aligned supplies of palladium group metals and other critical minerals used in automotive, clean energy, defense, and advanced electronics supply chains.

Average Trading Volume: 1,913,845

Technical Sentiment Signal: Buy

Current Market Cap: $39.58M

See more insights into KLTO stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1